Key Highlights

  • CG Oncology (NASDAQ:CGON) was trading up 19.77% at USD 77.61 on Friday, November 6, 2026, the day it reported third-quarter results, according to the screener.
  • PIVOT-006 Phase 3 topline data in intermediate-risk non-muscle invasive bladder cancer are expected in November 2026, and the third-quarter release did not include any efficacy numbers.
  • Cash, equivalents and marketable securities were USD 984.5 million at September 30, 2026, which the company expects to fund operations through 2029.
  • The third-quarter net loss was USD 56.9 million, or USD 0.64 per share, against USD 43.8 million, or USD 0.57, a year earlier.

Third-Quarter Update Puts the November Data Date in Focus

CG Oncology (NASDAQ:CGON) was trading up 19.77% at USD 77.61 on Friday, November 6, 2026, on the screener row. The company reported third-quarter results the same day, and the release held no trial data, so the update itself does not obviously explain a move of this size. What it did restate is that topline data from the Phase 3 PIVOT-006 trial of cretostimogene grenadenorepvec, given as adjuvant therapy in intermediate-risk and high-grade Ta non-muscle invasive bladder cancer, are due in November 2026. No company announcement tying the jump to a specific event was found, so the link to the data date is context, not a confirmed cause. Biotech shares often move ahead of binary readouts as traders position early, and that can add Volatility independent of the quarter's numbers.

Pipeline Calendar: PIVOT-006, BOND-003 and the BLA Filing

CG Oncology develops cretostimogene, an oncolytic immunotherapy delivered into the bladder, for non-muscle invasive bladder cancer. After PIVOT-006, the company expects 12-month data in December 2026 from BOND-003 Cohort P, in BCG-unresponsive papillary-only disease, and from CORE-008 Cohort CX. It also expects to complete its Biologics license application for BCG-unresponsive disease with carcinoma in situ in the fourth quarter of 2026. In October 2026 it appointed a Chief Commercial Officer, a step that usually comes ahead of a possible launch. A Phase 3 readout can move a single-asset biotech sharply in either direction, so the calendar carries as much risk as promise.

Losses, USD 984.5 Million of Cash and What Could Go Wrong

Third-quarter Revenue was USD 1.6 million against USD 1.7 million, and Research and Development expense rose to USD 39.2 million from USD 27.9 million on clinical trial costs. The operating loss was USD 63.2 million, and the net loss was USD 56.9 million, helped by USD 6.4 million of net interest income. Cash of USD 984.5 million compares with USD 742.2 million at December 31, 2025, and the company expects it to last through 2029, which lowers near-term financing risk. The main risk is the trial result itself: a miss or a mixed safety profile could reverse the gain, and a 19.77% rise ahead of binary news is already pricing in expectations.

Where Things Stand

Whether CG Oncology (NASDAQ:CGON) can hold the 19.77% jump depends mostly on the PIVOT-006 readout due in November 2026, and no one can say in advance how it will land. The shares were at USD 77.61 on the screener after a third-quarter update that confirmed USD 984.5 million of cash and a pipeline calendar, but contained no efficacy data. The Balance Sheet reduces financing pressure, while the stock now carries higher expectations into a binary event. Next markers are the topline data, December 12-month results and the fourth-quarter filing, plus any updated detail on commercial launch plans.